Jazz Pharmaceuticals (JAZZ) Misses Q1 EPS by 22c; Lowers Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. CRWD
4. VRTX
5. CHKP
6. ON
7. HNGE
8. INSP
9. AXSM
10. RXRX

Go back to Jazz Pharmaceuticals (JAZZ) Misses Q1 EPS by 22c; Lowers Outlook

Jazz Pharmaceuticals Announces First Quarter 2020 Financial Results

May 5, 2020 4:05 PM EDT

DUBLIN, May 5, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2020 and updated 2020 financial guidance.

"During this unprecedented time, I am proud of the commitment of our Jazz employees to supporting the continued delivery of our essential medicines to patients around the world," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals.  "Based on these efforts, we generated revenues of $535 million in the first quarter and continued to make progress toward our key 2020 objectives.  JZP-258 and lurbinectedin received priority... More